ruthenium has been researched along with sorafenib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bregman, H; Marmorstein, R; Meggers, E; Pagano, N; Qin, J; Streu, C; Xie, P | 1 |
| Atil, B; Berger, W; Groza, D; Heffeter, P; Jungwirth, U; Keppler, BK; Koellensperger, G; Körner, W; Kryeziu, K; Mohr, T | 1 |
| Lai, Y; Lu, N; Luo, S; Wang, H; Zhang, P | 1 |
3 other study(ies) available for ruthenium and sorafenib
| Article | Year |
|---|---|
The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
Topics: Animals; Benzenesulfonates; Cell Cycle Proteins; Crystallography, X-Ray; Humans; Ligands; Mice; Models, Molecular; Molecular Chaperones; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Ruthenium; Sorafenib | 2009 |
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Mice; Mice, SCID; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Ruthenium; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Hep G2 Cells; Humans; Lipid Peroxides; Liver Neoplasms; Prodrugs; Purines; Reactive Oxygen Species; Ruthenium; Sorafenib | 2022 |